Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsTreating Negative Symptoms in Schizophrenia: an UpdateNovel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamineWake-promoting pharmacotherapy for psychiatric disorders.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management.Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.
P2860
Q22241447-AF7852B5-CA6D-427E-989E-84496B780B08Q26744805-061925FD-779C-4433-AA0F-273F31E40D83Q26752974-33EF25E6-C64A-4539-B333-895605BDC29BQ34443394-4D793F07-7229-44E5-89E8-FFE67C0E4512Q35071909-A185A1A2-5F2E-42FA-AF61-B3ECF7FFE679Q35450483-5F4D3265-B49C-4413-80AB-F1DFE98C1402Q37637480-02E004BD-F157-47E0-940B-D20BF3798512Q38187948-FDA886AD-641A-41D0-9BA7-96F6F37C7D5BQ38221823-B620ED13-093A-41B0-96A0-913906A02704Q38268878-49C03C6A-CC5F-4916-94B5-936B2140C428Q38884279-72C483FA-ABDD-4184-A0D4-42F6AA1CE7FEQ46074240-14FBC6B1-DCB7-400A-9B0F-76F3028C925CQ47586487-969D3A78-6E9A-403D-AB3B-C366C10B77F6
P2860
Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@ast
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@en
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@nl
type
label
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@ast
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@en
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@nl
prefLabel
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@ast
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@en
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@nl
P2093
P2860
P356
P1476
Adjunctive lisdexamfetamine di ...... randomized-withdrawal phases.
@en
P2093
Bryan Dirks
Courtney Kirsch
Henry Nasrallah
Jean-Pierre Lindenmayer
Joseph Gao
Mary A Knesevich
Michael L Pucci
Robert A Lasser
P2860
P2888
P304
P356
10.1038/NPP.2013.111
P407
P577
2013-05-08T00:00:00Z
P5875
P6179
1041351898